BioCentury
ARTICLE | Company News

Gilead, GlobeImmune deal

November 18, 2016 9:27 PM UTC

GlobeImmune said Gilead terminated a 2011 deal granting Gilead rights to GS-4774. GlobeImmune regained all rights to the product. GS-4774, a Tarmogen comprising a heat-inactivated Saccharomyces cerevi...